Wedbush reiterates Outperform on Rocket Pharmaceuticals; $15 target
Wedbush reiterated an Outperform rating on Rocket Pharmaceuticals and set a $15.00 price target, implying upside of 339.9% versus the Sep 15 close of $3.41.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.